Bifogade filer
BONESUPPORT Q2 2023 EN
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BONESUPPORT Holding AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2023-07-13 08:00:00
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2023.
STRONG MOMENTUM FOR CERAMENT G IN THE US
APRIL – JUNE 2023
- Net sales increased by 88 percent (75 percent at constant exchange rates) and amounted to SEK 140.4 million (74.6).
- The North America (NA) segment reported a sales growth of 126 percent (107 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (24 percent at constant exchange rates).
- The gross margin amounted to 91.3 percent (89.0).
- Operating result before effects from the Group’s incentive programs amounted to SEK +13.6 million (-9.1). Reported operating result amounted to SEK +6.0 million (-14.9).
- Earnings per share before dilution were SEK +0.08 (-0.25).
- Earnings per share after dilution were SEK +0.08 (-0.25).
JANUARY – JUNE 2023
- Net sales increased by 85 percent (72 percent at constant exchange rates) and amounted to SEK 260.1 million (141.0).
- The North America (NA) segment reported a sales growth of 118 percent (100 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (27 percent at constant exchange rates).
- The gross margin amounted to 90.9 percent (89.7)
- Operating result before effects from the Group’s incentive programs amounted to SEK +18.2 million (-21.6). Reported operating result amounted to SEK +6.7 million (-31.3).
- Earnings per share before dilution were SEK +0.09 (-0.51).
- Earnings per share after dilution were SEK +0.08 (-0.51).
"Strong quarter, with increased market penetration for CERAMENT G." Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
- In May, a study was published of 53 patients, with an average follow-up time of 30 months, in which 100 percent of patients were able to avoid amputation when using CERAMENT G/V in the treatment of complex diabetic foot osteomyelitis cases.
- Strong long-term data with CERAMENT G for severe open fractures were presented in a study from Manchester University Hospital in May. The study was conducted with 81 patients with a mean follow-up time of 55.8 months.
EVENTS AFTER THE REPORTING PERIOD
Nothing to report.